MWA
AGIO icon

Marshall Wace Asia’s Agios Pharmaceuticals AGIO Stock Holding History

Marshall Wace Asia’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,405
Closed -$784K – 152
2020
Q3 		$784K Buy
+22,405
New +$982K 0.02% 114

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace Asia's AGIO Position: Q4 2020 in Review

Marshall Wace Asia sold out of Agios Pharmaceuticals (AGIO) in Q4 2020, closing a stake of 22,405 shares — an estimated $784K sold.

Marshall Wace Asia first reported a position in AGIO in Q3 2020 and held it in 1 quarter. The position peaked at $784K in Q3 2020. 200 funds tracked by Wall St. Rank hold AGIO as of Q4 2020.

  • Marshall Wace Asia reported no remaining Agios Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace Asia sold 22,405 Agios Pharmaceuticals shares in Q4 2020, an estimated $784K.
  • Marshall Wace Asia first reported a position in Agios Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Marshall Wace Asia's Agios Pharmaceuticals position peaked at $784K in Q3 2020.
  • 200 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2020.

Based on Marshall Wace Asia's 13F filing for Q4 2020, filed 16 Feb 2021.